Herbert Smith Freehills Kramer LLP v Insulet (CFI, 16 October 2025)
| Date | 16 October 2025 |
|---|---|
| Court | CFI |
| Division | Milan (IT) Central Division- Section |
| Type of action | Application RoP262.1 (b) |
| Case number(s) | UPC_CFI_941/2025 |
| Registry reference | UPC-CFI-0000941/2025 |
| Parties | Herbert Smith Freehills Kramer LLP v. 1) Insulet Corporation; 2) EOFLOW Co., Ltd. |
Official decision (PDF) · UPC registry entry
Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.
Dhenne Avocats · 10 October 2026
Our analysis
Summary
In an order of 16 October 2025, the judge-rapporteur of the Milan Central Division partly granted Herbert Smith Freehills Kramer’s request for access to the file of the proceedings Insulet v EOFLOW (UPC_CFI_380/2024). Only Insulet’s application and EOFLOW’s objection are to be provided, in redacted form, within five days. Access to the other eleven items requested, mostly exhibits, was refused. The order confirms that a third party relying on a mere need to understand the decision will obtain the pleadings, but seldom the exhibits.
Question
Does a law firm wishing to understand a decision better in order to advise its clients show a sufficient interest under Rule 262.1(b) to obtain access to the pleadings and exhibits?
Decision
Only in part. The judge examines the applicant’s specific interest and grants access only to documents that are essential to the stated purpose, weighing it against the parties’ legitimate interests and the general interest of justice, which includes preventing abusive requests. The redacted pleadings are enough to understand the decision. The exhibits are not needed and the risk of a scoping exercise prevails. Documents not mentioned in the decision of 22 July 2025 add nothing, and disclosing them would be disproportionate. Protected material (trade secrets, personal data) remains protected after the decision on the merits. No costs order was made, access proceedings not being contentious.
Key points for practice
- An applicant for access should define its purpose precisely: the extent of access is measured against that purpose, document by document.
- Parties resisting access should show that the documents sought played no part in the decision.
Provisions applied
- Agreement on a Unified Patent Court
- Arts 45 and 58
- Rules of Procedure
- Rules 262.1(b), 262.2 and 262A
- Case law cited
- Ocado Innovation v Autostore, Court of Appeal, 10 April 2024, Amgen v Sanofi-Aventis Deutschland, Munich Central Division, 20 September 2023, Abbott Diabetes Care v Sibio, Court of Appeal (UPC_CoA_480/2024 and UPC_CoA_481/2024)
Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.
Going further
Lexicon: Supplementary protection certificate (SPC), Biosimilar medicinal product, Launch at risk.
Dhenne Avocats blog: Pharmaceutical patents and the UPC: is the Court hostile to them?.
Publications by Matthieu Dhenne: The Launch Letter: How Generics and Biosimilars Should Write to Avoid UPC Urgency (Kluwer Patent Blog).
Source and translations
- Official source
- Unified Patent Court registry link recorded in the record
- Original language
- not recorded
- Translation available
- no translation recorded the firm’s French record is a summary, not a translation
- Date checked
- not recorded
Follow this case
Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.
Parties
- claimantHerbert Smith Freehills Kramer LLPFollow this party
- defendant1) Insulet CorporationFollow this party
- defendant2) EOFLOW Co., Ltd.Follow this party
Decisions in the same proceedings and documented appeals
What the record states
- Nature of the act
- Application RoP262.1 (b)
- Outcome (Dhenne Avocats summary)
- Le cabinet demandeur obtient copie expurgée de la demande d'Insulet et de l'objection d'EOFLOW. L'accès aux annexes est refusé, faute d'être indispensable au but invoqué.
- Appeal
- No appeal documented in the corpus, this does not mean that no appeal was lodged.
- Instance
- First-instance decision, whether it has become final is not recorded.
Related decisions cited in the analyses
- Ocado Innovation v Autostore (CoA, 10 April 2024) cited in this record
- Sanofi-Aventis Deutschland v Amgen (CFI, 20 September 2023) cited in this record
- Gowling WLG v Merz Therapeutics (CFI, 19 February 2026) cites this decision
Receive an alert
Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.